Valuation: Tenax Therapeutics, Inc.

Market Cap 78Cr 68Cr 63Cr 58Cr 110.09Cr 7.49TCr 111.8Cr 748.47Cr 293.75Cr 3.73TCr 294.73Cr 288.25Cr 13TCr P/E 2026 *
-9.38x
P/E 2027 * -8.25x
Enterprise Value 70Cr 61Cr 57Cr 52Cr 98Cr 6.68TCr 100Cr 667.69Cr 262.05Cr 3.33TCr 262.92Cr 257.14Cr 11TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day-9.27%
1 week-5.71%
1 month-11.38%
3 months+7.20%
6 months+5.79%
Current year+12.39%
1 week 13.65
Extreme 13.65
16.5
1 month 13.65
Extreme 13.65
19.4
Current year 10.25
Extreme 10.25
19.4
1 year 5.78
Extreme 5.78
19.4
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,135.04
10 years 2.77
Extreme 2.77
84,800
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 21/01/2025
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 69 25/02/2021
Date Insider Type Main position Quantity % Market Cap.
13/07/26 Fiscal year

Chief Executive Officer

17,438 0.0657%
11/05/26 Free

Chief Financial Officer

4,60,000 2.6748%
30/01/26 Other

Controller/Auditor

50,000 0.8008%
Change 5-day change 1-year change 3-year change Capi.($)
-9.27%-5.71%+120.26%-42.94% 78Cr
+0.69%+1.47%+0.35%+15.84% 4.85TCr
-2.41%-0.90%+411.96%+472.09% 3.99TCr
-1.16%+12.96%+28.81%+7.27% 3.87TCr
-1.88%-3.03%+5.69%+66.52% 3.51TCr
-1.74%+5.12%+14.44%+44.64% 2.98TCr
-0.21%-4.04%+36.40%+126.06% 1.61TCr
-2.85%-3.92% - - 1.61TCr
+1.29%+2.72%+3.31%+16.75% 1.36TCr
-1.19%-1.32%-1.73%-34.97% 1.26TCr
Average -1.70%+0.38%+68.83%+74.58% 2.51TCr
Weighted average by Cap. -0.82%+2.01%+80.34%+107.69%

Financials

2026 *2027 *
Net sales - -
Net income -7.49Cr -6.51Cr -6.06Cr -5.57Cr -11Cr -715.19Cr -11Cr -71Cr -28Cr -356.05Cr -28Cr -28Cr -1.19TCr -8.96Cr -7.79Cr -7.25Cr -6.66Cr -13Cr -855.31Cr -13Cr -85Cr -34Cr -425.81Cr -34Cr -33Cr -1.43TCr
Net Debt -8.47Cr -7.36Cr -6.85Cr -6.29Cr -12Cr -808.55Cr -12Cr -81Cr -32Cr -402.53Cr -32Cr -31Cr -1.35TCr -82L -71.28L -66.35L -60.92L -1.15Cr -78Cr -1.17Cr -7.82Cr -3.07Cr -39Cr -3.08Cr -3.01Cr -130.67Cr
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
31/26/31 $13.70 -9.27% 17,84,928
30/26/30 $15.10 +1.89% 19,66,773
29/26/29 $14.82 -6.20% 15,65,528
28/26/28 $15.80 -2.41% 15,60,344
27/26/27 $16.19 +11.42% 18,03,993
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
13.70USD
Average target price
35.30USD
Spread / Average Target
+157.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock